VolitionRX

VolitionRX reported an adjusted loss of $0.85 per share and revenue of $398,660 for Q2 2026, with both metrics below analyst estimates. Operating expenses fell 32% year‑on‑year, yet the company posted an operating loss of $7.3 million and held $2.8 million in cash at quarter‑end. Management highlights progress in sepsis, lung cancer and veterinary diagnostics programs and several partnerships, but declined to provide a full‑year revenue outlook due to high quarter‑to‑quarter volatility. The stock slipped slightly in after‑hours trading and is trading near its 52‑week low. » More on de.investing.com

VolitionRx published data showing that the Nu.Q NETs / H3.1 nucleosome test can distinguish sepsis from non-infectious systemic inflammation and correlates with disease severity. Studies across multiple countries indicate the test provides prognostic information on disease course, including organ failure and mortality, and offers incremental information compared with established scores such as APACHE-II and SOFA. VolitionRx is in talks with diagnostics companies to further develop the platform and estimates the addressable market at about $3.8 billion annually. » More on de.investing.com

VolitionRx and Lind Global signed a waiver and consent agreement after the company violated a minimum market capitalization covenant for two secured convertible notes. Lind Global waives certain remedies such as immediate acceleration or foreclosure, but explicitly reserves governed rights and may convert portions of the claim into common shares (conversion cap 4.99%). VolitionRx must pay an additional amount equal to 10% of the outstanding principal for each note; the waiver will be attached to the 10-Q, which will be filed no later than August 14, 2026. The breach occurs against the backdrop of a low market capitalization of USD 24.64 million, total debt of USD 11.7 million and a current ratio of 0.33; the company also reported strong revenue growth in Q1 2026, but an EPS of -0.97 and the resignation of director Mickie Henshall. » More on de.investing.com